- Conditions
- Urothelial Cancer, Receptors, Fibroblast Growth Factor
- Interventions
- Archival Tumor Tissue Sample
- Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Denver, Colorado • Newark, Delaware + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 41
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Plagiocephaly, Brachycephaly, Deformational Plagiocephaly, Deformational Posterior Plagiocephaly
- Interventions
- Cranial Remolding Orthosis
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 3 Months to 18 Months
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Metopic Craniosynostosis
- Interventions
- Allogenix Plus
- Biological
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Months to 36 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Deformational Plagiocephaly, Deformational Posterior Plagiocephaly, Brachycephaly, Torticollis, Congenital Muscular Torticollis
- Interventions
- Repositioning Therapy, Cranial Remolding Orthosis
- Other · Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 2 Months to 3 Months
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Craniosynostosis, Bleeding
- Interventions
- Tranexamic acid, saline
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma
- Interventions
- Brivanib, Irinotecan
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Craniosynostosis, Philadelphia Type Craniosynostosis
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Craniosynostosis
- Interventions
- neurobehavioral development
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 2 Months to 7 Years
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2015
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Westchester, Illinois • St Louis, Missouri + 1 more
- Conditions
- Solid Tumor Malignancy
- Interventions
- Pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 44
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Fort Myers, Florida • Miami, Florida + 4 more
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- BGJ398, BYL719
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Ann Arbor, Michigan • Detroit, Michigan + 4 more
- Conditions
- Craniosynostosis, Muenke Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2020
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Craniosynostosis
- Interventions
- biopsy
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 2 Months to 18 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- UC (Urothelial Cancer)
- Interventions
- pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 34
- States / cities
- Tucson, Arizona • San Diego, California • San Francisco, California + 31 more
- Conditions
- Craniosynostosis
- Interventions
- Epsilon-Aminocaproic Acid
- Drug
- Lead sponsor
- Paul Stricker
- Other
- Eligibility
- 2 Months to 24 Months
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Craniosynostosis
- Interventions
- Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hydrocephalus in Children, Epilepsy, Craniosynostoses, Traumatic Brain Injury
- Interventions
- McDESPOT
- Device
- Lead sponsor
- Memorial Healthcare System
- Other
- Eligibility
- Up to 19 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Hollywood, Florida
- Conditions
- Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
- Interventions
- Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
- Drug
- Lead sponsor
- Tyra Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more
- Conditions
- Plagiocephaly, Brachycephaly, Asymmetric Head
- Interventions
- MyCRO Band, Traditional CRO
- Device
- Lead sponsor
- Otto Bock HealthCare LP
- Industry
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Madison Heights, Michigan
- Conditions
- Urothelial Carcinoma
- Interventions
- Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more
- Conditions
- Craniosynostosis
- Interventions
- MR scan
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Plagiocephaly, Scaphocephaly, Brachycephaly
- Interventions
- Cranial cup device and Moldable positioner, Moldable positioner device
- Device
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 10 Days
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors
- Interventions
- INCB062079
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • New York, New York • Toledo, Ohio